Recruitment

Recruitment Status
Not yet recruiting
Estimated Enrollment
Same as current

Summary

Conditions
  • Celiac Disease
  • Allergic Rhinitis
  • Psoriasis
  • Alopecia Areata
  • Ankylosing Spondylitis
  • Anxiety Disorders
  • Asthma
  • Recurrent Depressive Disorder
  • Type 1 Diabetes
  • Multiple Sclerosis
  • Atopic Dermatitis
  • Psoriatic Arthritis
  • Sjogren's Syndrome
  • Polymyalgia Rheumatica
  • Crohn Disease
  • Rheumatoid Arthritis
  • Systemic Lupus Erythematosus
  • Ulcerative Colitis
  • Depressive Episode
  • Pernicious Anemia
  • Vitiligo
  • Grave's Disease
  • Hashimoto Thyroiditis
Type
Observational
Design
Observational Model: CohortTime Perspective: Retrospective

Participation Requirements

Age
Younger than 125 years
Gender
Both males and females

Description

The overall purpose of the first study (Study 1) is to describe the epidemiology of Alopecia areata (AA) and to assess the current level of primary care service utilisation and management patterns associated with patients diagnosed with AA. The overall purpose of the second study (study 2) is to ass...

The overall purpose of the first study (Study 1) is to describe the epidemiology of Alopecia areata (AA) and to assess the current level of primary care service utilisation and management patterns associated with patients diagnosed with AA. The overall purpose of the second study (study 2) is to assess the prevalence and incidence of mental health conditions (depressive episodes, recurrent depressive disorder and anxiety disorder) in adult patients diagnosed with AA relative to a control population of patients without a diagnosis of AA. In addition, the study will determine both the treatment, 'sick day' and unemployment burden. Treatment burden comprises that of medications and psychological interventions used to treat mental health conditions in adult patients diagnosed with Alopecia areata. The overall purpose of the third study (Study 3) is to assess the prevalence and incidence of atopic and autoimmune conditions in adult patients diagnosed with AA relative to a control population of patients without AA.

Tracking Information

NCT #
NCT04239521
Collaborators
  • Pfizer
  • University of Surrey
Investigators
Study Director: Andrew McGovern, MD Momentum Data